Our findings have extended the regulatory mechanism of GRB2 expression from an epigenetic perspective and revealed a new mechanism for regulating GRB2 expression through m5C modification, indicating that downregulation of m5C modification in GRB2 may also have therapeutic benefits in ESCC via decreasing GRB2 expression. The gene discussed is GRB2; the disease is esophageal squamous cell carcinoma.